Trastuzumab Biosimilars Market Size, Share, Revenue, Trends And Drivers For 2024-2033

March 30, 2024 12:15 AM AEDT | By EIN Presswire
 Trastuzumab Biosimilars Market Size, Share, Revenue, Trends And Drivers For 2024-2033
Image source: EIN Presswire

LONDON, GREATER LONDON, UK, March 29, 2024 /EINPresswire.com/ -- The global market reports from The Business Research Company have been updated with the most recent market sizing data for 2024 and projections extended to 2033

The Business Research Company’s “Trastuzumab Biosimilars Global Market Report 2024 is a comprehensive source of information that covers every facet of the market. As per TBRC’s market forecast, the trastuzumab biosimilars market size is predicted to reach $14.69 billion in 2028 at a compound annual growth rate (CAGR) of 28.3%.

The growth in the trastuzumab biosimilars market is due to the rising prevalence of breast and gastric cancer. North America region is expected to hold the largest trastuzumab biosimilars market share. Major players in the trastuzumab biosimilars market include Pfizer Inc., Outlook Therapeutics lnc., Merck & Co., Amgen Inc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd.

Trastuzumab Biosimilars Market Segments
• By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
• By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
• By Distribution Channel: Hospital Pharmacy, Online Pharmacy
• By Geography: The global trastuzumab biosimilars market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Learn More On The Market By Requesting A Free Sample (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=3400&type=smp

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that is designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive.

Read More On The Trastuzumab Biosimilars Global Market Report At:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Trastuzumab Biosimilars Market Characteristics
3. Trastuzumab Biosimilars Market Trends And Strategies
4. Trastuzumab Biosimilars Market – Macro Economic Scenario
5. Trastuzumab Biosimilars Market Size And Growth
……
27. Trastuzumab Biosimilars Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Market
29. Trastuzumab Biosimilars Market Future Outlook and Potential Analysis
30. Appendix

Browse Through More Similar Reports By The Business Research Company:

Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Hormones Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Rituximab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Contact Information
The Business Research Company: https://www.thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]

Check out our:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.